

Outlook Therapeutics, Inc. Logo

Outlook Therapeutics to Present at Two Upcoming Investor Conferences

September 8, 2020

MONMOUTH JUNCTION, N.J., Sept. 08, 2020 (GLOBE NEWSWIRE) -- [Outlook Therapeutics, Inc.](#) (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced that [Lawrence Kenyon, President, CEO and CFO](#) of Outlook Therapeutics, will present at two upcoming investor conferences in September.

The following are the details for the conferences.

[H.C. Wainwright 22nd Annual Global Investment Conference](#)

- Event: Fireside Chat Discussion and Q&A
- Date and Time: Monday, September 14, 2020 at 4:30 PM EDT

[Oppenheimer Fall Healthcare Life Sciences & MedTech Summit](#)

- Event: Fireside Chat Discussion and Q&A
- Date and Time: Monday, September 21, 2020 at 2:30 PM EDT

In addition to the presentations, management will also be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend either of the conferences.

A live video webcast of the presentations will be accessible on the [Events](#) page of the [Investors](#) section of the Outlook Therapeutics website, [outlooktherapeutics.com](#), approximately two hours after each event and will be archived for 90 days following the event.

About Outlook Therapeutics, Inc.

Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010 / LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab-vikg for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. Outlook Therapeutics expects to file ONS-5010 with the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway. For more information, please visit [www.outlooktherapeutics.com](#).

CONTACTS:

Media Inquiries:

Jessica Morris
Account Executive
LaVoie Health Science
T: 857.701.9731
jmorris@lavoiehealthscience.com

Investor Inquiries:

Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 833.475.8247
OTLK@jtcir.com



Source: Outlook Therapeutics, Inc.